Sanofi secures rights to Ascenta's experimental cancer drugs

06/6/2010 | Reuters

Biotech firm Ascenta Therapeutics agreed to license its cancer drug candidates, including MI-773 and MI-519-64, to Sanofi-Aventis. The deal entitles Ascenta to get as much as $398 million from Sanofi.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN